An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to assess the effect of two doses of teriflunomide, in
comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants
with relapsing MS.
Key secondary objective was to assess the effect of the two doses of teriflunomide, in
comparison to placebo, on disability progression.
Other secondary objectives were:
- To assess the effect of the two doses of teriflunomide in comparison to placebo on:
- Fatigue;
- Health-related quality of life, a measure of the impact of the participant's health
on his or her overall well being.
- To evaluate the safety and tolerability of teriflunomide.